

STATEMENT

Global biopharmaceutical CEOs response to reforms introduced in Germany

BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said:

“The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively impact the availability of new medicines for patients and lead to reduced levels of investment in research and development.

“The German Government must act to reverse the current direction which undermines Germany’s position as a leading location for pharmaceutical innovation and investment.”

About the Biopharmaceutical CEO Roundtable ([BCR](#))

The BCR is a global policy forum where the CEOs of [International Federation of Pharmaceutical Manufacturers and Associations](#) (IFPMA) member companies discuss global health policies impacting biomedical innovation. Where possible, the BCR organizes meetings with government officials and policymakers.

For further information, please contact:

Elliot Dunster

Executive Director, Strategy and Communications

+41 79 502 76 90

e.dunster@ifpma.org